BOSTON (MarketWatch) — Anthera Pharmaceuticals ANTH -47.51% shares plunged nearly 50% to $3.67 on Monday during the first trading session after it announced it was halting a key Phase III study. Late Friday, Anthera said it stopping a Phase III clinical trial for its heart-drug candidate varespladib over concerns that it was ineffective.
If you enjoy the content at iBankCoin, please follow us on TwitterRelated Articles
$MSFT Pink Slips 18k Jobs
July 17, 2014
$GS & $JPM Manage to Beat Net Profit Estimates
July 15, 2014